
Commentary|Videos|February 25, 2026
How RB-1355 Addresses Unmet Needs in Lymphoma Treatment
Author(s)Paolo Strati, MD
Fact checked by: Paige Britt
Advertisement
In an interview with Targeted Oncology, Paolo Strati, MD, associate professor in the Department of Lymphoma/Myeloma in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discussed the current limitations in lymphoma treatment and how RB-1355 addresses critically unmet needs of patients.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Iberdomide, the First CELMoD for Relapsed/Refractory Multiple Myeloma
2
Alert-Based ePRO Monitoring Reduces Fatigue in Metastatic Breast Cancer
3
ASTRO Issues Updated Clinical Practice Guideline on RT for Pancreatic Cancer
4
FAQ: When and How to Discontinue Lenalidomide Maintenance in Multiple Myeloma
5



































